Results 151 to 160 of about 52,949 (209)

Treatment-Emergent Isolated EGFR C797S Mutation Following First-Line Osimertinib-Based Combination Therapy: A Case Report and Literature Review. [PDF]

Respirol Case Rep
Nguyen TH, Nguyen HG, Le TH.
europepmc   +1 more source

Traditional Chinese medicine reprograms the tumor microenvironment to overcome EGFR-TKI resistance: mechanisms and therapeutic perspectives. [PDF]

Front Pharmacol
Yao Y, Gao S, Wang JP.
europepmc   +1 more source

Polycationic dendrimers synergizes with gefitinib to overcome EGFR^Ex19Del-driven resistance in non-small-cell lung cancer. [PDF]

Discov Oncol
Cruz A, Abreu B, Mendes C, Lemos I, Freitas-Dias C, Gomes R, Sousa B, Gonçalves F, Ramalho JS, Barral DC, Bonifácio VDB, Serpa J.   +11 more
europepmc   +1 more source

Coordinated DNA 5-mC and RNA m⁵C methylation epigenetically regulates MZF1 splice variants to drive EGFR-TKI resistance. [PDF]

Exp Mol Med
Zhang H, Pang Y, Liu B, Wang D, Zhao N, Wang X, Wei P, Lin J, Lin S.   +8 more
europepmc   +1 more source

Pulmonary Cryptococcal Infection Complicating Gefitinib Therapy in a Patient With EGFR L858R-Positive Lung Adenocarcinoma: A Case Report. [PDF]

Clin Case Rep
Wang Y, Wang Q, Liao J, Zhou Y, Yang F, Li GF, Wu C, Jiang T.   +7 more
europepmc   +1 more source

Effect of EGFR-TP53 co-mutation on the efficacy of EGFR-TKIs in patients with advanced NSCLC and therapeutic strategies: A retrospective study. [PDF]

Medicine (Baltimore)
Feng X, Liu L.
europepmc   +1 more source

Design, Synthesis of Novel Quinazolinone Derivatives and Evaluation of EGFR Kinase Inhibition Activity via In Vitro and In Silico Studies. [PDF]

Chem Biol Drug Des
Kaya AZ, Evren AE, Akalın-Çiftçi G, Yurttaş L.   +3 more
europepmc   +1 more source

A real-world pharmacovigilance study of four anti-non-small cell lung cancer drugs using the WHO-VigiAccess database. [PDF]

Medicine (Baltimore)
Fang C, Wu J, Hu C, Liu Q, Ma W, Zhang L, Hua P, Ding Y, Zhong Y.   +8 more
europepmc   +1 more source

Rezivertinib in <i>EGFR</i>-Mutated Non-Small Cell Lung Cancer Patients with Central Nervous System Metastasis: Central Nervous System Efficacy from the Phase III REZOR Study. [PDF]

Cancer Commun (Lond)
Yang S, Zhao Y, Sun M, Bi M, Zhu B, Chen Z, Yu H, Zhang L, Wu L, Zhou R, Yao W, Li X, Han Z, Wang K, Wang L, Wen M, Guo Y, Lin Y, Sun S, Guo S, Yi T, Zhao W, Yu Z, Qin J, Pan Y, He Z, Ye F, Shi H, Fang J, Ma R, Lu H, Zhang H, Shi J, Gao J, Cui J, Li M, Yi S, Cang S, Shu Y, Zhang D, Peng J, Gao F, Wang T, Zhou A, Shi Y.   +44 more
europepmc   +1 more source

Individualized pharmacotherapy: background and development. [PDF]

Ann Transl Med
Jørgensen JT, Westergaard N.
europepmc   +1 more source